498 6944Incyte Reports Third Quarter 2013 Financial Results; Updates Shareholders on Key Clinical Programs Sample Clauses


498-6944Incyte Reports Third-Quarter 2013 Financial Results; Updates Shareholders on Key Clinical Programs · $60.2 million of third-quarter net product revenues from Jakafi, reflecting solid growth in underlying demand· Top-line results from Phase II trial of ruxolitinib in patients with refractory metastatic pancreatic cancer suggest a demonstrable survival benefit in a well-defined subgroup of patients· Positive Phase II data from trials of oral JAK1 inhibitor, INCB39110, in psoriasis and rheumatoid arthritis presented at recent scientific meetingsConference Call Scheduled Today at 8:30 a.m. ETWILMINGTON, DE — Oct. 31, 2013 — Incyte Corporation (Nasdaq: INCY) today reported third-quarter 2013 financial results, including revenue from Jakafi® (ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF). The Company also described: positive top-line results of its Phase II trial (RECAP) of ruxolitinib in patients with refractory metastatic pancreatic cancer; positive Phase II proof-of-concept data recently presented at key scientific meetings for its lead JAK1 inhibitor, INCB39110; and progress for several of its other key clinical programs.